These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29659588)

  • 1. Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months.
    Wolf S; Hoffmann VS; Habicht A; Kauke T; Bucher J; Schoenberg M; Werner J; Guba M; Andrassy J
    PLoS One; 2018; 13(4):e0194975. PubMed ID: 29659588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infections after kidney transplantation: A comparison of mTOR-Is and CNIs as basic immunosuppressants. A systematic review and meta-analysis.
    Wolf S; Lauseker M; Schiergens T; Wirth U; Drefs M; Renz B; Ryll M; Bucher J; Werner J; Guba M; Andrassy J
    Transpl Infect Dis; 2020 Jun; 22(3):e13267. PubMed ID: 32072714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
    BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zeng J; Zhong Q; Feng X; Li L; Feng S; Fan Y; Song T; Huang Z; Wang X; Lin T
    Front Immunol; 2021; 12():663602. PubMed ID: 34539621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis.
    Moore J; Middleton L; Cockwell P; Adu D; Ball S; Little MA; Ready A; Wheatley K; Borrows R
    Transplantation; 2009 Feb; 87(4):591-605. PubMed ID: 19307799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
    Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
    Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.
    Andrassy J; Hoffmann VS; Rentsch M; Stangl M; Habicht A; Meiser B; Fischereder M; Jauch KW; Guba M
    Transplantation; 2012 Dec; 94(12):1208-17. PubMed ID: 23269449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
    Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
    Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F; Andrés A; Oppenheimer F
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation.
    Roodnat JI; Hilbrands LB; Hené RJ; de Sévaux RG; Smak Gregoor PJ; Kal-van Gestel JA; Konijn C; van Zuilen A; van Gelder T; Hoitsma AJ; Weimar W
    Transplantation; 2014 Jul; 98(1):47-53. PubMed ID: 24521775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
    Webster AC; Lee VW; Chapman JR; Craig JC
    Transplantation; 2006 May; 81(9):1234-48. PubMed ID: 16699448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
    Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.
    Yan HL; Zong HT; Cui YS; Li N; Zhang Y
    Transplant Proc; 2014 Jun; 46(5):1302-13. PubMed ID: 24935293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
    Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
    Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L; Kamar N
    J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM
    Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
    Kumar J; Bridson JM; Sharma A; Halawa A
    Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.